Neuromodulation Devices Market

Neuromodulation Devices Market, by Device Type (Spinal Cord Stimulation Devices, Deep Brain Stimulation Devices, Sacral Nerve Stimulation Devices, Vagus Nerve Stimulation Devices, and Gastric Electric Stimulation Devices), by Application (Pain Management, Neurological and Movement Disorder Management, Musculoskeletal Disorder Management, Metabolism and GIT Management and Others (Incontinence Management, etc.)) by End User (Hospitals, Ambulatory Surgical Centers, Specialized Clinics, and Others (Nursing Facilities, etc.)) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Neuromodulation devices stimulate nerves with electrical signals, pharmaceutical agents, or other forms of energy neurostimulation that provides pain relief by blocking the transmission of pain signals before they reach the brain. Neuromodulation devices are implantable medical devices, which introduce therapeutic solutions to some chronic diseases through electric stimulation or medication. Neuromodulation devices are segmented into five major technologies, namely: spinal cord stimulation devices, deep brain stimulation devices, vagus nerve stimulation devices, sacral nerve stimulation devices and gastric electric stimulation devices. Neuromodulation devices deliver electrical impulses to the nerves and the brain by treating disorders such as deafness, chronic pain, and Parkinson’s disease. Lectrical stimulation uses electrotherapy for treating spinal injuries and muscle weakness associated with neurological disorders. It has a property to activate electrical impulse and transmit signals to the electrodes of neuromodulation device, which causes depolarization and, in turn, reduces pain and improves the muscle strength. Different types of electrical stimulation devices are designed to treat various diseases such as pain management, obesity, and others.

Market Dynamics

Increasing product approvals by regulatory authorities are expected to drive the global neuromodulation devices market growth over the forecast period. For instance, on April 19, 2023, BIOTRONIK, a medical technology company, announced the U.S. Food and Drug Administration (FDA) approval for Prospera, a Spinal Cord Stimulation (SCS) system. The system features RESONANCE, the first and multiphase stimulation paradigm, paired with Embrace One, a patient-centric care model that makes proactive care possible by offering automatic, objective, daily remote monitoring, and ongoing management and support. This approval marks the launch of the company’s new business segment, BIOTRONIK Neuro.

Key features of the study:

This report provides an in-depth analysis of the global neuromodulation devices market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global neuromodulation devices market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

The key companies covered as a part of this study include Medtronic, BD, LivaNova, Axonics, Inc., ShiraTronics, Abbott, Bioventus, Neuronetics, NEVRO CORP, Integer Holdings Corporation, BIOTRONIK, NeuroPace, Inc., NeuroMetrix, Inc., Helius Medical Technologies, Inc., and Synapse Biomedical Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics

The global neuromodulation devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuromodulation devices market

Detailed Segmentation:

• Global Neuromodulation Devices Market, Device Type:
• Spinal Cord Stimulation Devices
• Deep Brain Stimulation Devices
• Sacral Nerve Stimulation Devices
• Vagus Nerve Stimulation Devices
• Gastric Electric Stimulation Devices
• Global Neuromodulation Devices Market, Application:
• Pain Management
• Neurological and Movement Disorder Management
• Musculoskeletal Disorder Management
• Metabolism and GIT Management
• Others (Incontinence Management, etc.)
• Global Neuromodulation Devices Market, By End User:
• Hospitals
• Ambulatory Surgical Centers
• Specialized Clinics
• Others (Nursing Facilities, etc.)
• Global Neuromodulation Devices Market, By Region:
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Medtronic
• BD
• LivaNova
• Axonics, Inc.
• ShiraTronics
• Abbott
• Bioventus
• Neuronetics
• NEVRO CORP
• Integer Holdings Corporation
• BIOTRONIK
• NeuroPace, Inc.
• NeuroMetrix, Inc.
• Helius Medical Technologies, Inc.
• Synapse Biomedical Inc.